Who Paid My Doc
Kimberly McDonald
Public Health & General Preventive Medicine Apex, NC Medical Doctor
NPI 1053313064 CMS profile 820099
2034 Creekside Landing Dr, Apex, NC 27502
General payments
$43
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$149,845
Through program year 2023, Kimberly McDonald of Apex, NC is reported in the CMS Open Payments database as having received $43 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $149,845 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 28th percentile of Public Health & General Preventive Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $21 | 1 | |
| 2019 | General | $22 | 2 |
Beside peers
- Kimberly McDonald
- Public Health & General Preventive Medicine median
- Middle half of Public Health & General Preventive Medicine
- National median
In program year 2025, general payments to Kimberly McDonald were reported at $0. Among 185 Public Health & General Preventive Medicine profiles paid that year, the median was $99 and the middle half received between $32 and $365.
Show as a table
| Year | Kimberly McDonald | Public Health & General Preventive Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $22 | $99 | $22–$287 | $163 |
| 2020 | $0 | $101 | $21–$478 | $114 |
| 2021 | $0 | $99 | $31–$856 | $132 |
| 2022 | $0 | $79 | $24–$340 | $149 |
| 2023 | $21 | $102 | $28–$326 | $160 |
| 2024 | $0 | $98 | $27–$291 | $164 |
| 2025 | $0 | $99 | $32–$365 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Public Health & General Preventive Medicine in North Carolina
Lakisha Highe
Public Health & General Preventive Medicine · Charlotte, NC
Asha Stern
Public Health & General Preventive Medicine · Huntersville, NC
John Pittman
Public Health & General Preventive Medicine · Raleigh, NC
Scott Shapiro
Public Health & General Preventive Medicine · Indian Trail, NC
Devlin Cole
Public Health & General Preventive Medicine · Asheville, NC
Jack Taylor
Public Health & General Preventive Medicine · Durham, NC
Related records
Public Health & General Preventive Medicine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Public Health & General Preventive Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.